Abbott Laboratories (ABT) has seen its stock decline by 22% over the past year, underperforming other healthcare stocks in the S&P 500. The company is expected to report low revenue for Q1 on April 16, but analysts anticipate double-digit growth in subsequent quarters. Despite recent struggles, Abbott's strong financial position and free cash flow support ongoing annual dividend increases, with yields currently at yearly highs. Technical indicators suggest the stock is oversold, indicating potential for a price rebound in the near term.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
